{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T21:51:35Z","timestamp":1789595495796,"version":"build-2803163510"},"reference-count":44,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.com.au","thrombosisresearch.com","clinicalkey.es","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Thrombosis Research"],"published-print":{"date-parts":[[2024,11]]},"DOI":"10.1016\/j.thromres.2024.109175","type":"journal-article","created":{"date-parts":[[2024,9,28]],"date-time":"2024-09-28T19:09:09Z","timestamp":1727550549000},"page":"109175","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":8,"special_numbering":"C","title":["Hemophilia A: Economic burden, therapeutic advances, and future forecasts in the Middle East and North Africa region"],"prefix":"10.1016","volume":"243","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8112-5275","authenticated-orcid":false,"given":"Radwa Ahmed","family":"Batran","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohab","family":"Kamel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ayman","family":"Bahr","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ahmed","family":"Khalil","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohamed","family":"Elsokary","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"7","key":"10.1016\/j.thromres.2024.109175_bb0005","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1542\/pir.34.7.289","article-title":"Hemophilia: in review","volume":"34","author":"Zimmerman","year":"2013","journal-title":"Pediatr. Rev. [Internet]."},{"issue":"5","key":"10.1016\/j.thromres.2024.109175_bb0010","doi-asserted-by":"crossref","first-page":"54","DOI":"10.3390\/jcm6050054","article-title":"Hemophilia care in the pediatric age","volume":"6","author":"Bertamino","year":"2017","journal-title":"J. Clin. Med. [Internet]."},{"issue":"9824","key":"10.1016\/j.thromres.2024.109175_bb0015","doi-asserted-by":"crossref","first-page":"1447","DOI":"10.1016\/S0140-6736(11)61139-2","article-title":"Modern haemophilia care","volume":"379","author":"Berntorp","year":"2012","journal-title":"Lancet [Internet]"},{"issue":"5954","key":"10.1016\/j.thromres.2024.109175_bb0020","doi-asserted-by":"crossref","first-page":"817","DOI":"10.1126\/science.1180660","article-title":"Genotype analysis identifies the cause of the \u201croyal disease\u201d","volume":"326","author":"Rogaev","year":"2009","journal-title":"Science (80- ) [Internet]"},{"key":"10.1016\/j.thromres.2024.109175_bb0025","author":"Salen"},{"issue":"2","key":"10.1016\/j.thromres.2024.109175_bb0030","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1182\/blood-2008-03-143586","article-title":"Acquired factor VIII inhibitors","volume":"112","author":"Franchini","year":"2008","journal-title":"Blood [Internet]"},{"key":"10.1016\/j.thromres.2024.109175_bb0035","author":"Centers for Disease Control and Prevention"},{"key":"10.1016\/j.thromres.2024.109175_bb0040","author":"The Perth Blood Institute"},{"key":"10.1016\/j.thromres.2024.109175_bb0045","author":"World Federation of Hemophilia"},{"key":"10.1016\/j.thromres.2024.109175_bb0055","author":"Indiana Hemophilia & Thrombosis Center"},{"issue":"23","key":"10.1016\/j.thromres.2024.109175_bb0060","doi-asserted-by":"crossref","first-page":"1773","DOI":"10.1056\/NEJM200106073442307","article-title":"The hemophilias \u2014 from royal genes to gene therapy","volume":"344","author":"Mannucci","year":"2001","journal-title":"N. Engl. J. Med. [Internet]"},{"key":"10.1016\/j.thromres.2024.109175_bb0065","author":"National Bleeding Disorders Foundation"},{"issue":"6","key":"10.1016\/j.thromres.2024.109175_bb0070","first-page":"479","article-title":"Factor VIII replacement is still the standard of care in haemophilia A","volume":"17","author":"Aledort","year":"2019","journal-title":"Blood Transfus [Internet]"},{"issue":"4","key":"10.1016\/j.thromres.2024.109175_bb0075","doi-asserted-by":"crossref","first-page":"692","DOI":"10.1111\/j.1538-7836.2005.01204.x","article-title":"Definition of major bleeding in clinical investigations of antihemostatic medicinal products in non-surgical patients","volume":"3","author":"Schulman","year":"2005","journal-title":"J. Thromb. Haemost. [Internet]"},{"key":"10.1016\/j.thromres.2024.109175_bb0080","author":"National Organization for Rare Disorders (NORD)"},{"issue":"4","key":"10.1016\/j.thromres.2024.109175_bb0085","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1586\/ehm.10.33","article-title":"Immunomodulation for inhibitors in hemophilia A: the important role of Treg cells","volume":"3","author":"Miao","year":"2010","journal-title":"Expert. Rev. Hematol. [Internet]."},{"issue":"4","key":"10.1016\/j.thromres.2024.109175_bb0090","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1111\/ejh.13108","article-title":"The socioeconomic burden of patients affected by hemophilia with inhibitors","volume":"101","author":"D\u2019Angiolella","year":"2018","journal-title":"Eur. J. Haematol. [Internet]."},{"issue":"4","key":"10.1016\/j.thromres.2024.109175_bb0095","doi-asserted-by":"crossref","first-page":"668","DOI":"10.1111\/hae.13758","article-title":"Regional variation and cost implications of prescribed extended half-life factor concentrates among U.S. Haemophilia Treatment Centres for patients with moderate and severe haemophilia","volume":"25","author":"Croteau","year":"2019","journal-title":"Haemophilia [Internet]"},{"issue":"4","key":"10.1016\/j.thromres.2024.109175_bb0100","first-page":"449","article-title":"Health care costs and resource utilization among commercially insured adult patients with hemophilia A managed with FVIII prophylaxis in the United States","volume":"28","author":"Thornburg","year":"2022","journal-title":"J. Manag. Care Spec. Pharm. [Internet]"},{"issue":"4","key":"10.1016\/j.thromres.2024.109175_bb0105","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1111\/hae.14347","article-title":"Real-world cost estimates of initiating emicizumab in US patients with haemophilia A","volume":"27","author":"Samelson-Jones","year":"2021","journal-title":"Haemophilia [Internet]"},{"issue":"3","key":"10.1016\/j.thromres.2024.109175_bb0110","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1111\/hae.13981","article-title":"Characterizing female patients with haemophilia A: administrative claims analysis and medical chart review","volume":"26","author":"Farej","year":"2020","journal-title":"Haemophilia [Internet]"},{"issue":"1","key":"10.1016\/j.thromres.2024.109175_bb0115","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1111\/hae.14171","article-title":"Disease burden and remaining unmet need in patients with haemophilia A treated with primary prophylaxis","volume":"27","author":"O\u2019Hara","year":"2021","journal-title":"Haemophilia [Internet]."},{"issue":"6","key":"10.1016\/j.thromres.2024.109175_bb0120","first-page":"647","article-title":"Health care costs and resource use of managing hemophilia A: a targeted literature review","volume":"29","author":"Chen","year":"2023","journal-title":"J. Manag. Care Spec. Pharm. [Internet]"},{"issue":"2","key":"10.1016\/j.thromres.2024.109175_bb0125","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1111\/j.1365-2516.2011.02692.x","article-title":"Healthcare expenditures for males with haemophilia and employer-sponsored insurance in the United States, 2008","volume":"18","author":"Guh","year":"2012","journal-title":"Haemophilia [Internet]."},{"issue":"2","key":"10.1016\/j.thromres.2024.109175_bb0130","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1111\/j.1365-2516.2011.02713.x","article-title":"Health care expenditures for Medicaid-covered males with haemophilia in the United States, 2008","volume":"18","author":"Guh","year":"2012","journal-title":"Haemophilia [Internet]."},{"issue":"2","key":"10.1016\/j.thromres.2024.109175_bb0135","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1111\/j.1365-2516.2011.02623.x","article-title":"The economics of inpatient on-demand treatment for haemophilia with high-responding inhibitors: a US retrospective data analysis","volume":"18","author":"Pokras","year":"2012","journal-title":"Haemophilia [Internet]."},{"issue":"11","key":"10.1016\/j.thromres.2024.109175_bb0140","doi-asserted-by":"crossref","first-page":"798","DOI":"10.3111\/13696998.2014.953679","article-title":"Costs and utilization of hemophilia A and B patients with and without inhibitors","volume":"17","author":"Armstrong","year":"2014","journal-title":"J. Med. Econ. [Internet]."},{"issue":"S4","key":"10.1016\/j.thromres.2024.109175_bb0145","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1111\/hae.14531","article-title":"Therapeutic and technological advancements in haemophilia care: quantum leaps forward","volume":"28","author":"Lewandowska","year":"2022","journal-title":"Haemophilia [Internet]"},{"issue":"1","key":"10.1016\/j.thromres.2024.109175_bb0150","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1146\/annurev-med-012017-043332","article-title":"Entering the modern era of gene therapy","volume":"70","author":"Anguela","year":"2019","journal-title":"Ann. Rev. Med. [Internet]"},{"issue":"5","key":"10.1016\/j.thromres.2024.109175_bb0155","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1056\/NEJMra1706910","article-title":"Gene therapy","volume":"381","author":"High","year":"2019","journal-title":"N. Engl. J. Med. [Internet]."},{"issue":"1","key":"10.1016\/j.thromres.2024.109175_bb0160","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1007\/s12185-018-2513-4","article-title":"Advances in gene therapy for hemophilia: basis, current status, and future perspectives","volume":"111","author":"Ohmori","year":"2020","journal-title":"Int. J. Hematol. [Internet]"},{"key":"10.1016\/j.thromres.2024.109175_bb0165","doi-asserted-by":"crossref","first-page":"S151","DOI":"10.1111\/jth.12957","article-title":"Gene therapy in an era of emerging treatment options for hemophilia B","volume":"13","author":"Monahan","year":"2015","journal-title":"J. Thromb. Haemost. [Internet]"},{"issue":"9","key":"10.1016\/j.thromres.2024.109175_bb0170","doi-asserted-by":"crossref","first-page":"1099","DOI":"10.1080\/14712598.2022.2002842","article-title":"Hemophilia A gene therapy: current and next-generation approaches","volume":"22","author":"Pipe","year":"2022","journal-title":"Expert. Opin. Biol. Ther. [Internet]."},{"issue":"15","key":"10.1016\/j.thromres.2024.109175_bb0175","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1016\/j.omtm.2019.08.015","article-title":"Clinical considerations for capsid choice in the development of liver-targeted AAV-based gene transfer","author":"Pipe","year":"2019","journal-title":"Mol. Ther. Methods Clin. Dev. [Internet]"},{"issue":"S3","key":"10.1016\/j.thromres.2024.109175_bb0180","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1111\/hae.14023","article-title":"Uncertainty in an era of transformative therapy for haemophilia: addressing the unknowns","volume":"27","author":"Pierce","year":"2021","journal-title":"Haemophilia [Internet]."},{"key":"10.1016\/j.thromres.2024.109175_bb0185","author":"DUPHAT"},{"key":"10.1016\/j.thromres.2024.109175_bb0190","doi-asserted-by":"crossref","first-page":"141","DOI":"10.2147\/JBM.S291536","article-title":"Optimizing haemophilia care in resource-limited countries: current challenges and future prospects","volume":"14","author":"Ndoumba-Mintya","year":"2023","journal-title":"J. Blood Med. [Internet]."},{"issue":"3","key":"10.1016\/j.thromres.2024.109175_bb0195","doi-asserted-by":"crossref","first-page":"e517","DOI":"10.5001\/omj.2023.99","article-title":"Challenges for hemophilia patient care across the Middle East and North Africa","volume":"38","author":"Noun","year":"2023","journal-title":"Oman Med. J. [Internet]."},{"key":"10.1016\/j.thromres.2024.109175_bb0200","unstructured":"The London School of Economics and Political Science. Pharmaceutical pricing and reimbursement in the Middle East and North Africa region [Internet]. 2018 [cited 2023 Nov 27]. Available from: chrome-extension:\/\/efaidnbmnnnibpcajpcglclefindmkaj\/https:\/\/www.lse.ac.uk\/business\/consulting\/assets\/documents\/pharmaceutical-pricing-and-reimbursement-in-the-middle-east-and-north-africa-region.pdf."},{"key":"10.1016\/j.thromres.2024.109175_bb0205","author":"Grand View Research"},{"key":"10.1016\/j.thromres.2024.109175_bb0210","author":"Market Data Forecast"},{"key":"10.1016\/j.thromres.2024.109175_bb0215","unstructured":"Egypt hemophilia market analysis [Internet]. [cited 2023 Nov 30]. Available from: https:\/\/www.insights10.com\/report\/egypt-hemophilia-market-analysis\/#:~:text=Egypt Hemophilia Market is valued,the forecast period 2023-2030."},{"issue":"1","key":"10.1016\/j.thromres.2024.109175_bb0225","doi-asserted-by":"crossref","first-page":"130","DOI":"10.3390\/hematolrep15010014","article-title":"Haemophilia A: a review of clinical manifestations, treatment, mutations, and the development of inhibitors","volume":"15","author":"Sarmiento Doncel","year":"2023","journal-title":"Hematol. Rep. [Internet]."},{"issue":"9","key":"10.1016\/j.thromres.2024.109175_bb0230","doi-asserted-by":"crossref","first-page":"e689","DOI":"10.1016\/S2352-3026(22)00209-5","article-title":"Achieving access to haemophilia care in low-income and lower-middle-income countries: expanded Humanitarian Aid Program of the World Federation of Hemophilia after 5 years","volume":"9","author":"Pierce","year":"2022","journal-title":"Lancet Haematol. [Internet]."}],"container-title":["Thrombosis Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0049384824003074?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0049384824003074?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,10,16]],"date-time":"2024-10-16T11:02:11Z","timestamp":1729076531000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0049384824003074"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,11]]},"references-count":44,"alternative-id":["S0049384824003074"],"URL":"https:\/\/doi.org\/10.1016\/j.thromres.2024.109175","relation":{},"ISSN":["0049-3848"],"issn-type":[{"value":"0049-3848","type":"print"}],"subject":[],"published":{"date-parts":[[2024,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Hemophilia A: Economic burden, therapeutic advances, and future forecasts in the Middle East and North Africa region","name":"articletitle","label":"Article Title"},{"value":"Thrombosis Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.thromres.2024.109175","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Elsevier Ltd. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"109175"}}